An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination
Documented refractory or relapsed and refractory multiple myeloma
Refractory to proteosome inhibitor and lenalidomide, and to last treatment
Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment
Measurable disease at screening
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria:

Active plasma cell leukemia
Prior treatment with pomalidomide
Unable to tolerate thromboembolic prophylaxis while on the study
Prior autologous stem cell transplant within 12 weeks
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C